193 related articles for article (PubMed ID: 32632941)
21. [Hepatic tumors and radiotherapy].
Rio E; Mornex F; Peiffert D; Huertas A
Cancer Radiother; 2016 Sep; 20 Suppl():S174-8. PubMed ID: 27521035
[TBL] [Abstract][Full Text] [Related]
22. Radiotherapy for Hepatocellular Carcinoma.
Yu Y; Feng M
Semin Radiat Oncol; 2018 Oct; 28(4):277-287. PubMed ID: 30309638
[TBL] [Abstract][Full Text] [Related]
23. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis.
Hara K; Takeda A; Tsurugai Y; Saigusa Y; Sanuki N; Eriguchi T; Maeda S; Tanaka K; Numata K
Hepatology; 2019 Jun; 69(6):2533-2545. PubMed ID: 30805950
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome.
Dobrzycka M; Spychalski P; Rostkowska O; Wilczyński M; Kobiela P; Grąt M; Dell'Acqua V; Høyer M; Jereczek-Fossa BA
Acta Oncol; 2019 Dec; 58(12):1706-1713. PubMed ID: 31464155
[No Abstract] [Full Text] [Related]
25. Role of stereotactic body radiation therapy for hepatocellular carcinoma.
Sanuki N; Takeda A; Kunieda E
World J Gastroenterol; 2014 Mar; 20(12):3100-11. PubMed ID: 24696597
[TBL] [Abstract][Full Text] [Related]
26. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
[TBL] [Abstract][Full Text] [Related]
27. A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.
Jackson WC; Suresh K; Maurino C; Feng M; Cuneo KC; Ten Haken RK; Lawrence TS; Schipper MJ; Owen D
Radiother Oncol; 2019 Dec; 141():101-107. PubMed ID: 31431377
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
29. Radiotherapy for Hepatocellular Carcinoma in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise.
Mitin T; Degnin C; Chen Y; Shirvani S; Gillespie E; Hoffe S; Latifi K; Nabavizadeh N; Dengina N; Chernich M; Usychkin S; Kharitonova E; Egorova Y; Pankratov A; Tsimafeyeu I; Thomas CR; Tjulandin S; Likhacheva A
J Cancer Educ; 2020 Feb; 35(1):105-111. PubMed ID: 30467774
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiation therapy for hepatocellular carcinoma.
Lo SS; Dawson LA; Kim EY; Mayr NA; Wang JZ; Huang Z; Cardenes HR
Discov Med; 2010 May; 9(48):404-10. PubMed ID: 20515608
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who failed or were unsuitable for transarterial chemoembolization.
Lo CH; Huang WY; Lee MS; Lin KT; Lin TP; Chang PY; Fan CY; Jen YM
Eur J Gastroenterol Hepatol; 2014 Mar; 26(3):345-52. PubMed ID: 24384685
[TBL] [Abstract][Full Text] [Related]
32. Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA.
Sanuki N; Takeda A; Oku Y; Eriguchi T; Nishimura S; Aoki Y; Mizuno T; Iwabuchi S; Kunieda E
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):306-11. PubMed ID: 24411601
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma.
Klein J; Korol R; Lo SS; Chu W; Lock M; Dorth JA; Ellis RJ; Mayr NA; Huang Z; Chung HT
Future Oncol; 2014 Nov; 10(14):2227-41. PubMed ID: 25471036
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival.
Robbins JR; Schmid RK; Hammad AY; Gamblin TC; Erickson BA
Cancer Med; 2019 Mar; 8(3):928-938. PubMed ID: 30701703
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma.
Jeong Y; Jung J; Cho B; Kwak J; Jeong C; Kim JH; Park JH; Kim SY; Shim JH; Kim KM; Lim YS; Lee HC; Yoon SM
BMC Cancer; 2018 Apr; 18(1):416. PubMed ID: 29653562
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiation therapy: A novel treatment modality for inoperable hepatocellular carcinoma.
Meng M; Wang H; Zeng X; Zhao L; Yuan Z; Wang P; Hao X
Drug Discov Ther; 2015 Oct; 9(5):372-9. PubMed ID: 26632546
[TBL] [Abstract][Full Text] [Related]
37. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
Rim CH; Kim HJ; Seong J
Radiother Oncol; 2019 Feb; 131():135-144. PubMed ID: 30773180
[TBL] [Abstract][Full Text] [Related]
38. Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls.
Mastrocostas K; Jang HJ; Fischer S; Dawson LA; Munoz-Schuffenegger P; Sapisochin G; Kim TK
Abdom Radiol (NY); 2019 May; 44(5):1795-1807. PubMed ID: 30710166
[TBL] [Abstract][Full Text] [Related]
39. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Eggert T; Greten TF
Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma.
Jin H; Chalkidou A; Hawkins M; Summers J; Eddy S; Peacock JL; Coker B; Kartha MR; Good J; Pennington M;
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e143-e154. PubMed ID: 32951952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
